SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

HPV4 not associated with autoimmune conditions

By Leave a Comment

Infectious Disease News

Posted September 13, 2010

BOSTON — The quadrivalent human papillomavirus vaccine did not raise the risk for developing autoimmune conditions, according to data presented here at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.

In a study sponsored by Merck and conducted on behalf of the Gardasil Safety Team, researchers investigated the safety of the quadrivalent HPV vaccine (HPV4; Gardasil, Merck). The researchers honed in on identifying 16 prespecified rheumatologic, endocrine and neurologic or ophthalmologic autoimmune conditions.

During the post-licensure, observational study, the researchers monitored girls and women in managed care organizations who received at least one dose of HPV4 between August 2006 and March 2008. Follow-up lasted for 6 months after administration of each dose.

The researchers found 11 conditions among a random sample of girls and women who had at least a 12-month health care plan before HPV4 vaccination. Clinicians reviewed medical records to verify diagnosis and determine time of disease onset. Incidence rates for each condition were also established for vaccinated and unvaccinated participants during case identification and review.

Más mercado (y víctimas) de la vacuna VPH

By Leave a Comment

Publicado por Miguel Jara el

Spain
13 de Septiembre de 2010

La campaña para expandir la polémica vacunación contra el virus del papiloma humano toma fuerza. Hasta ahora sólo se podía vacunar a las niñas pero la Comisión Europea ha extendido su administración a mujeres de hasta 45 años.

Hay algunas cosas que llaman la atención. La primera de ellas es que antes decían que esta vacuna estaba indicada para las jóvenes que no habían iniciado relaciones sexuales ya que según un estudio realizado con una de las marcas del preparado, Gardasil, del laboratorio Merck, si la joven estaba infectada había un 44,6% de posibilidades de contraer cáncer de útero. Ahora parece que obvian este estudio. Desde la Asociación de Afectadas por la Vacuna contra el Papiloma opinan:

“Creemos que este dato no se puede obviar y todas las mujeres deberían hacerse una citología o pruebas antes de recibir la vacuna para ver si están infectadas, de lo contrario en lugar de prevenir la hipotética posibilidad de contraer cáncer de útero, incrementarían esta posibilidad en un 44,6%“.

Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Men.

By Leave a Comment

Pubmed
J Infect Dis. 2010 Sep 2

Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, Jay N, Aboulafia D, Cohn DL, Einstein MH, Saah A, Mitsuyasu RT, Palefsky JM.

Abstract
Background. Human immunodeficiency virus type 1 (HIV-1)-infected men are at increased risk for anal cancer. Human papillomavirus (HPV) vaccination may prevent anal cancer caused by vaccine types. Methods. AIDS Malignancy Consortium Protocol 052 is a single-arm, open-label, multicenter clinical trial to assess the safety and immunogenicity of the quadrivalent HPV (types 6, 11, 16, and 18) vaccine in HIV-1-infected men. Men with high-grade anal intraepithelial neoplasia or anal cancer by history or by screening cytology or histology were excluded. Men received 0.5 mL intramuscularly at entry, week 8, and week 24. The primary end points were seroconversion to vaccine types at week 28, in men who were seronegative and without anal infection with the relevant HPV type at entry, and grade 3 or higher adverse events related to vaccination. Results. There were no grade 3 or greater adverse events attributable to vaccination among the 109 men who received at least 1 vaccine dose. Seroconversion was observed for all 4 types: type 6 (59 [98%] of 60), type 11 (67 [99%] of 68), type 16 (62 [100%] of 62), and type 18 (74 [95%] of 78). No adverse effects on CD4 counts and plasma HIV-1 RNA levels were observed. Conclusions. The quadrivalent HPV vaccine appears safe and highly immunogenic in HIV-1-infected men. Efficacy studies in HIV-1-infected men are warranted. Clinical trials registration. NCT 00513526 .

PMID: 20812850 [PubMed – as supplied by publisher]

Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy

By Leave a Comment

American Association for Cancer Research
Francesca M. Carozzi1, Maria L. Tornesello2, Elena Burroni1, Giovanna Loquercio2, Giuseppe Carillo3, Claudio Angeloni4, Aurora Scalisi5, Rosalba Macis6, Francesco Chini7, Franco M. Buonaguro2, Paolo Giorgi Rossi7 and for the HPV Prevalence Italian Working Group

Corresponding Author:
Paolo Giorgi Rossi, Laziosanità, Via di Santa Costanza, 53, Rome 00198, Italy. E-mail: giorgirossi@asplazio.it

Abstract

Background: The aim of this multicentric study was to identify human papillomavirus (HPV) type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia 2/3 (CIN2/3) in Italy.

Methods: Cases were sampled through the electronic databases at the pathology units of eight centers in six regions from central and southern Italy. HPV types were detected from paraffin-embedded tissue samples and cervical specimens through amplification of HPV DNA with GP5+/GP6+ primers, followed by genotyping with reverse line blot (RLB). Untyped HPV-positive samples were sequenced. HPV-negative samples underwent nested PCR, followed by either RLB or sequencing. Finally, the remaining HPV-negative samples were amplified with primers targeting the virus E6 to E7 regions.

Women & Children First – Politician rediscovers Chivalry in Gardasil Debate

By Leave a Comment

ComeLook.org
10 September 2010
Although it’s very unusual for an ambitious politician to tell a potential voter to not communicate with him (“not to waste politician’s time”), in Ireland at least, highlighting the “not appropriate” subject of vaccine safety can provoke such a response.

When a campaigner wrote two short emails to a Wexford local politician in late 2008 raising concerns about the HPV vaccine Gardasil and suggesting he do some research into the associated side effects, the local politician’s response was “Please refrain from sending me any further misinformed and unrequested junk spam”.

Mairead Hilliard, of Irish Vaccine Informed Parents, wrote to Counciller Joe Ryan (now Mayor of Wexford, pop 18000), after she noticed that he had joined an online Facebook group campaigning for reinstatement of the cervical cancer mass vaccination program in Ireland.

News

Videos

Contact